Roots Analysis

MARCH 8, 2023

Over time, various research studies have demonstrated the potential of exosomes ( membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. Targeted Drug Delivery: Ability to cross blood brain barrier cause lesser systemic effects and low toxicity.

RNA 52

RNA Drug Delivery DNA Development 52

Roots Analysis

FEBRUARY 18, 2022

Myeloid cells represent a group of cells containing granulocytes, monocytes, macrophages, mast cells and dendritic cells, which play a key role in innate immunity. Myeloid Cells Targeting Therapeutics Market. These cells are found in abundance in the tumor microenvironment and inflamed areas. Our Social Media Platform. Web: [link].

Drug Delivery Systems 52

Drug Delivery Systems Immune Response Clinical Trials Clinical Trials 52

Drug Discovery World

AUGUST 9, 2023

Darren Mercer, Chief Executive of CSP, said: “We are thrilled to acquire AxeroVision, and in particular the pipeline product AXR-270 which contains a novel selective glucocorticoid receptor agonist formulated in a cutting-edge drug delivery system that overcomes the issues of poor compliance and inefficient delivery of conventional eye drops.”

Drugs 52

Drugs Drug Delivery Systems Drug Delivery Life Science 52

XTalks

JANUARY 17, 2023

The US Food and Drug Administration (FDA) granted approval to AstraZeneca’s Airsupra (albuterol/budesonide), formerly known as PT027, for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in individuals aged 18 years and older who have asthma.

FDA Approval 97

FDA Approval Containment Allergies Drugs 97

The Pharma Data

OCTOBER 27, 2020

European market launch of both COVID-19 tests planned for Q1 2021. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic. 25-minute RT-PCR lab test to complement 15-minute rapid test. About XPhyto Therapeutics Corp.

RNA 52

RNA Drug Delivery Production In-Vitro 52

The Pharma Data

NOVEMBER 2, 2020

We see a natural opportunity to apply XPhyto’s drug formulation expertise and Vektor’s proven drug delivery platforms to these emerging APIs,” said Hugh Rogers, CEO and Director of XPhyto. from 2017 to 2023 according to Allied Market Research. .” About XPhyto Therapeutics Corp.

Production 52

Production Development Drug Delivery Drugs 52

The Pharma Data

DECEMBER 28, 2020

Stetsenko has helped acquire, build and exit businesses via public markets and raising capital for companies in the technology, healthcare, communications and natural resources sectors. a publicly-listed company investing in blockchain technology solutions for capital markets and other sectors that can benefit from tokenization.

Containment 52

Containment Drug Delivery Compliance Marketing 52

The Pharma Data

DECEMBER 20, 2020

It is our continual objective to broaden our product scope, and Transcend, with its experienced management team, is a perfect foothold for us in the fast-growing market for psychedelics molecules and complements our existing pipeline of treatments. “We are very pleased to close our acquisition of Transcend. About BetterLife Pharma Inc.

Drug Delivery 52

Drug Delivery Containment Production Development 52

Roots Analysis

FEBRUARY 16, 2022

In earlier times, container closure integrity testing was not regarded as an essential step in the process of manufacturing. The company developing drug product through such an intense process, use to consider container closure system only for packaging of the product. [1] Container Closure Integrity Testing Services Market.

Containment 52

Containment Packaging Packaging Drug Delivery Systems 52

The Pharma Data

JANUARY 3, 2021

The information in the press release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). . +46 7686 650 11. 2 Proof of Concept.

Containment 52

Containment Bioavailability Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 26, 2020

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. Finnish time. About Nanoform. Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.

Containment 52

Containment Medicine Bioavailability Clinical Trials 52

The Pharma Data

OCTOBER 20, 2020

I look forward to working closely with my TLC colleagues and our external partners to bring these important medicines to markets across the globe.” This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Cautionary Note on Forward-Looking Statements.

Licensing 40

Licensing Licensing Drug Delivery Business Development 40

The Pharma Data

DECEMBER 14, 2020

is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. About BetterLife Pharma Inc. BetterLife Pharma Inc.

Drug Delivery 40

Drug Delivery Containment Manufacturing Drugs 40

The Pharma Data

JANUARY 17, 2021

The Company will continue to leverage its scientific expertise and operations in Europe and North America for product development and optimization while it plans to add significant commercial experience in the fields of manufacturing, distribution, marketing and sales. Drug Formulations and Delivery. XPhyto Therapeutics Corp.

Production 40

Production Drug Delivery Development Drugs 40

The Pharma Data

NOVEMBER 9, 2020

is accelerating the next-generation drug delivery, diagnostic, and phytochemical investment opportunities: precision transdermal and oral dissolvable drug dosage forms; rapid, low-cost infectious disease and oral health screening tools; and validation of approved cannabinoid-based therapeutics focused on European markets.

Development 40

Development Drugs Drug Delivery Production 40

The Pharma Data

NOVEMBER 4, 2020

is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and phyto-therapeutic investment opportunities: precision transdermal and oral dissolvable drug dosage forms; rapid, low-cost infectious disease and oral health screening tools; and emerging plant-based therapeutics focused on European markets.

Drug Delivery 40

Drug Delivery Production Manufacturing Life Science 40

The Pharma Data

JUNE 26, 2021

The PDS Marketing Authorisation Application has also been validated by the European Medicines Agency and is currently under review. 13 PDS contains a customised formulation of ranibizumab not approved by regulatory authorities. Portal is an extension study evaluating the long-term safety and efficacy of PDS in nAMD.

Drug Delivery 52

Drug Delivery Clinical Trials Clinical Trials Medicine 52

The Pharma Data

DECEMBER 2, 2020

The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Forward Looking Statements.

In-Vitro 40

In-Vitro Sales Containment Production 40

The Pharma Data

OCTOBER 27, 2020

The technology enhances the delivery of ingredients to and through the skin and is protected by patents in eleven countries. Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. Ovation trades on the CSE under the symbol OVAT.

Sales 52

Sales Production Drug Delivery Development 52

The Pharma Data

NOVEMBER 4, 2020

The Company offers a portfolio of non-prescription skincare products and early to commercial stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin.

Licensing 40

Licensing Licensing Dermatology Production 40

XTalks

MAY 30, 2023

The patch itself is made of biodegradable nanocellulose and contains no plastic additives. The Global ECG Patch Market The global ECG patch and holter monitor market , estimated to be around $13 billion and projected to grow at a 17.5 This device is designed such that the electronic components can be easily removed and reused.

Drug Delivery 98

Drug Delivery Drug Delivery Systems Manufacturing Contamination 98

The Pharma Data

DECEMBER 2, 2020

The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Forward-Looking Statements.

Sales 40

Sales In-Vitro Containment Development 40

XTalks

MAY 18, 2023

The wireless charger — the transmitter — contains a metallic coil that converts electrical energy into a magnetic field, which is then collected and reverted into electricity by the receiver inside the implanted device. Our wireless charging for titanium cans changes all of that.” billion in 2022. billion by 2032.

Development 96

Development Packaging Packaging Manufacturing 96

Roots Analysis

MARCH 16, 2023

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. Furthermore, these drug candidates can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Roots Analysis

JANUARY 17, 2024

They offer several advantages over traditional drug delivery systems ( such as vials and syringes ), including reduced chances of dosing errors, increased patient compliance and decreased risk of microbial contamination. However, this needle system does not contain a proper locking system, therefore, increased the chances of leakage.

Drug Delivery 40

Drug Delivery Contamination Drugs Production 40

The Pharma Data

JANUARY 27, 2021

The addition of in-house, scalable commercial drug manufacturing capability is expected to add significant value and optionality to XPhyto’s drug formulation business. In 2020, XPhyto reported significant advancements in four drug formulation development programs. About XPhyto Therapeutics Corp.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

Roots Analysis

FEBRUARY 13, 2023

Further, the biggest challenge in this domain is the purification which involve the use of hazardous solvents / materials and stability of drug products ( thereby, requiring specialized facilities and cold chain transportation).

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

The Pharma Data

JANUARY 27, 2021

Utilizing drug delivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus.

In-Vitro 52

In-Vitro Containment Drugs Production 52

The Pharma Data

DECEMBER 17, 2020

Ampholipad recently achieved an important milestone in its global commercialization efforts, having signed the first term sheet in Latin America, with options in other markets. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Source link.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Containment 40

XTalks

AUGUST 30, 2022

Strategic leaders know how to think critically and navigate through daily challenges that are bound to emerge in this competitive market. The pharmaceutical industry deals with threats such as product liability, cyberthreats, supply chain disruptions, competition from generic drugs and more. Transformational Leadership.

Life Science 105

Life Science Generic Drugs Drug Delivery Compliance 105

Pharmaceutical Technology

APRIL 16, 2023

But with the advent of injection site absorption enhancers, drug delivery device innovations, as well as the recent primary container options, the practical subcutaneous self-administration of large-volume parenterals is becoming possible. For them, intravenous infusion in a hospital setting is the only option. autoinjector.

Protein 130

Protein Containment Drug Delivery Drugs 130

Pharmaceutical Technology

FEBRUARY 3, 2023

In 2021, 72% of newly approved drugs were small molecules, and almost 50% of new drugs approved were OSD. While the industry is seeing advances in alternative drug delivery systems, oral solid doses, such as pills, capsules and soft gels, remain at the forefront of the industry.

Contamination 130

Contamination Manufacturing Containment Production 130